Table 1.
MDA details and current status of the programme to eliminate LF in SEAR countries as of 2018–2019
| Country | Number of IUs | Population of IUs (millions) | Number of treatments delivered (millions) 2001–2019 | Number of treatments consumed (millions) 2001–2019 | % IUs MDA no longer required as of 2019 | Current programme status |
|---|---|---|---|---|---|---|
| India | 256 | 630 | 6727.3 | 47 103.4 | 38 | MDA and surveillance |
| Indonesia | 236 | 102 | 494.9 | 312.6 | 42 | MDA and surveillance |
| Myanmar | 45 | 40 | 327.4 | 292.8 | 71 | MDA and surveillance |
| Nepal | 63 | 25 | 175.9 | 130.8 | 76 | MDA and surveillance |
| Timor-Leste | 13 | 12.8 | 5.9 | 4.5 | 100* | MDA likely to be stopped |
| Bangladesh | 19 | 33 | 265.3 | 221 | 100 | Surveillance |
| Thailand | 350 | 0.17 | 1.2 | 1.1 | 100 | LF elimination acknowledged |
| Sri Lanka | 8 | 10.46 | 52.8 | 44.8 | 100 | LF elimination acknowledged |
| Maldives | 1 | <0.01 | 0.007 | 0.006 | 100 | LF elimination acknowledged |
Abbreviations: IU, intervention unit; LF, lymphatic filariasis; MDA, mass drug administration; TAS, Transmission Assessment Survey.
*Subject to TAS outcome.